Inhibitors and antibodies blocking the interactions between CTLA­4 or PD­1 and their cognate ligands, have demonstrated to be effective in various tumor types, with low immune­mediated toxicity [197], including HCC [190]. Here, CTLA4 is linked to neoplasm.